^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mammaglobin-A DNA vaccine

    i
    Other names: mammaglobin-A DNA vaccine, WUSM-MGBA-01, mam-A DNA vaccine
    Associations

    News

    Trials
    Company:
    GSK, Washington University School of Medicine in St. Louis
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    10d
    Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial. (PubMed, Cancer Immunol Res)
    In addition, post-vaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.
    P1 data • Journal
    |
    ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    ER positive
    |
    mammaglobin-A DNA vaccine
    almost2years
    Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Washington University School of Medicine | Phase classification: P1b --> P1
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    HER-2 amplification • HER-2 negative
    |
    mammaglobin-A DNA vaccine
    3years
    Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov)
    P1b, N=27, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jan 2029 --> Aug 2028 | Trial primary completion date: Jun 2024 --> Apr 2022
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    HER-2 amplification • HER-2 negative
    |
    mammaglobin-A DNA vaccine
    3years
    Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov)
    P1b, N=56, Recruiting, Washington University School of Medicine | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    HER-2 amplification • HER-2 negative
    |
    mammaglobin-A DNA vaccine